Narcolepsy research: Past, present, and future perspectives

Archives Italiennes de Biologie

Volumn 142, Issue 4, 2004, Pages 479-486

  Fromherz, S ^a   Mignot, Emmanuel ^a  

^a Stanford California and Cofounder   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; HISTAMINE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; OREXIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTOIMMUNITY; CATAPLEXY; CELL TRANSPLANTATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONFERENCE PAPER; GENE MUTATION; GENE THERAPY; GENETICS; HUMAN; NARCOLEPSY; NEUROPATHOLOGY; NONHUMAN; PSYCHOPHARMACOTHERAPY; SIDE EFFECT;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC MARKERS; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, NEUROLOGICAL; NARCOLEPSY; NEUROPEPTIDES; NEUROSCIENCES; SLEEP;

EID: 4644272704     PISSN: 00039829     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. BAKER, T.L., FOUTZ, A.S., MCNERNEY, V., MITLER, M.M., AND DEMENT, W.C. Canine model of narcolepsy: genetic and developmental determinants. Exp. Neurol., 75: 729-742, 1982.
2. BASSETTI C. AND ALDRICH M.S. Narcolepsy. Neurol. Clin., 14: 545-571, 1996.
3. BEUCKMANN, C.T. AND YANAGISAWA, M. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J. Mol. Med., 80: 329-342, 2002.
4. BROUGHTON, R.J., FLEMING, J.A., GEORGE, C.F., HILL, J.D., KRYGER, M.H., MOLDOFSKY, H., MONTPLAISIR, J.Y., MOREHOUSE, R.L, MOSCOVITCH, A., AND MURPHY, W.F. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology, 49: 444-451, 1997.
5. CHEMELLI, R.M., WILLIE, J.T., SINTON, C.M., ELMQUIST, J.K., SCAMMELL, T., LEE, C., RICHARDSON, J.A., WILLIAMS, S.C., XIONG, Y., KISANUKI, Y., FITCH, T.E., NAKAZATO, M., HAMMER, R.E., SAPER, C.B. AND YANAGISAWA, M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 98: 437-451, 1999.
6. DANIELS, L.E. Narcolepsy. Medicine, 13: 1-122, 1934.
7. DE LECEA, L., KILDUFF, T.S., PEYRON, C., GAO, X.-B., FOYE, P.E., DANIELSON, P.E., FUKUHARA, C., BATTENBERG, E.L.F., GAUTVIK, V.T., BARTLETT, F.S., FRANKEL, W.N., VAN DEN POL, A.N., BLOOM, F.E., GAUTVIK, K.M. AND SUTCLIFFE, J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA, 95: 322-327, 1998.
8. DUGOVIC, C., KOEHL, M., RONTAL, A.D., TOYOTA, H., LOVENBERG, T.W., AND TUREK, F.W. Sleep in mice lacking the histamine H3 receptor, a putative genetic animal model for REM sleep behavior disorder. Sleep, (suppl.) 25: A114-A115, 2002.
9. FISCHER, F. Epileptoide schlafzustände. Arch. F. Psychiat., 8: 200-203, 1878.
10. FRY, J.M. Treatment modalities for narcolepsy. Neurology, (suppl. 1) 50: S43-S48, 1998.
11. GéLINEAU, J. De la narcolepsie. Gaz. d. hôp., 53: 626-628, 1880.
12. GUILLEMINAULT, C., DEMENT, W.C., AND PASSOUANT, P. Narcolepsy. New York, NY: Spectrum Publications, 1975.
13. HONDA, Y., ASAKE, A., TANAKA, Y., AND JUJI, T. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res., 1: 254, 1983.
14. HONDA, Y., DOI, Y., JUJI, T., AND SATAKE, M. Narcolepsy and HLA: positive DR2 as a prerequisite for the development of narcolepsy. Folia. Psychiatr. Neurol. Jpn., 38: 360, 1984.
15. HORVATH, T.L., PEYRON, C., DIANO, S., IVANOV, A., ASTON-JONES, G., KILDUFF, T.S., AND VAN DEN POL, A.N. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol., 415: 145-159, 1999.
16. HUBLIN, C. Narcolepsy: current drug treatment options. CNS Drugs, 6: 426-436, 1996.
17. HUNGS, M., FAN, J., LIN, L., LIN, X., MAKI, R.A., AND MIGNOT E. Identification and functional nalysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res., 11: 531-539, 2001.
18. KNECHT, C.D., OLIVER, J.E., REDDING, R., SELCER, R. AND JOHNSON, G. Narcolepsy in a dog and a cat. J. Am. Vet. Med. Assoc., 162: 1052-3, 1973.
19. LAMMERS, G.J., ARENDS, J., DECLERCK, A.C., FERRARI, M.D., SCHOUWINK, G., AND TROOST, J. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep, 16: 216-220, 1993.
20. LIN, L., FARACO, J., LI, R., KADOTANI, H., ROGERS, W., LIN, X., QIU, X., DE JONG, P.J., NISHINO, S. AND MIGNOT, E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98: 365-76, 1999.
21. LOEWENFELD, L. Ueber narkolepsie. München. med. Wchnschr., 49: 1041-1045, 1902.
22. MARCUS, J.N., ASCHKENASI, C.J., LEE, C.E., CHEMELLI, R.M., SAPER, C.B., YANAGISAWA, M., AND ELMQUIST, J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol., 435: 6-25, 2001.
23. MIGNOT, E. Genetic and family aspects of narcolepsy. Neurology, (suppl 1) 50: S16-S22, 1998.
24. MIGNOT, E., HAYDUK, R., BLACK, J., GRUMET, F.C., AND GUILLEMINAULT, C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep, 20: 1012-1020, 1997.
25. MIGNOT, E., KIMURA, A., LATTERMANN, A., LIN, X., YASUNAGA, S., MUELLER-ECKHARDT, G., RATTAZZI, C., LIN, L., GUILLEMINAULT, C., GRUMET, F.C., MAYER, G., DEMENT, W.C., AND UNDERHILL, P. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens, 49: 329-341, 1997.
26. MIGNOT, E., LAMMERS, G.J., RIPLEY, B., OKUN, M., NEVSIMALOVA, S., OVEREEM, S., VANKOVA, J., BLACK, J., HARSH, J., BASSETTI, C., SCHRADER, H., AND NISHINO, S. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol., 59: 1553-1562, 2002.
27. MIGNOT, E., LIN, X., ARRIGONI, J., MACAUBAS, C., OLIVE, F., HALLMAYER, J., UNDERHILL, P., GUILLEMINAULT, C., DEMENT, W.C. AND GRUMET, F.C. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in caucasian and black americans. Sleep, 17: S60-S67, 1994.
28. MIGNOT, E., WANG, C., RATTAZZI, C., GAISER, C., LOVETT, M., GUILLEMINAULT, C., DEMENT, W.C., AND GRUMET, F.C. Genetic linkage of autosomal recessive canine narcolepsy with a μ immunoglobulin heavy-chain switch-like segment. Proc. Natl. Acad. Sci. USA, 88: 3475-3478, 1991.
29. MITLER, M.M., BOYSEN, B.G., CAMPBELL, L. AND DEMENT, W.C. Narcolepsy-cataplexy in a female dog. Exp. Neurol., 45: 332-40, 1974.
30. NISHINO, S., FUJIKI, N., YOSHIDA, Y., AND MIGNOT, E. The effects of hypocretin-1 (orexin a) in hypocretin receptor 2 gene mutated and hypocretin ligand-deficient narcoleptic dogs. Sleep, (abstract supplement) 26: A287, 2003.
31. NISHINO, S., RIPLEY, B., OVEREEM, S., LAMMERS, G.J., AND MIGNOT, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet, 355: 39-40, 2000.
32. PARMENTIER, R., OHTSU, H., DJEBBARA-HANNAS, Z., VALATX, J.L., WATANABE, T., AND LIN, J.S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci., 22: 7695-7711, 2002.
33. PEYRON, C., FARACO, J., ROGERS, W., RIPLEY, B., OVEREEM, S., CHARNAY, Y., NEVSIMALOVA, S., ALDRICH, M., REYNOLDS, D., ALBIN, R., LI, R., HUNGS, M., PEDRAZZOLI, M., PADIGARU, M., KUCHERLAPATI, M., FAN, J., MAKI, R., LAMMERS, G.J., BOURAS, C., KUCHERLAPATI, R., NISHINO, S., AND MIGNOT, E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med., 6: 991-997, 2000.
34. PEYRON, C., TIGHE, D.K., VAN DEN POL, A.N., DE LECEA, L., HELLER, H.C., SUTCLIFFE, J.G., AND KILDUFF, T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci., 18: 9996-10015, 1998.
35. RECHTSCHAFFEN A. AND DEMENT W.C. Studies on the relation of narcolepsy, cataplexy, and sleep with low voltage random EEG activity. Res. Publ. Assoc. Res. Nerv. Ment. Dis., 45: 488-505, 1967.
36. SAKURAI, T., AMEMIYA, A., ISHII, M., MATSUZAKI, I., CHEMELLI, R.M., TANAKA, H., WILLIAMS, S.C., RICHARDSON, J.A., KOZLOWSKI, G.P., WILSON, S., ARCH, J.R., BUCKINGHAM, R.E., HAYNES, A.C., CARR, S.A., ANNAN, R.S., MCNULTY, D.E., LIU, W.S., TERRETT, J.A., ELSHOURBAGY, N.A., BERGSMA, D.J., AND YANAGISAWA, M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92: 573-585, 1998.
37. SCRIMA, L., HARTMAN, P.G., JOHNSON, F.H., THOMAS, E.E., AND HILLER, F.C. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep, 13: 479-490, 1990.
38. STRECKER, R.E., NALWALK, J., DAUPHIN, L. J., THAKKAR, M.M., CHEN, Y., RAMESH, V., HOUGH, L.B., AND MCCARLEY, R.W. Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience, 113: 663-670, 2002.
39. TAHERI, S., ZEITZER, J.M., AND MIGNOT, E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Ann. Rev. Neurosci., 25: 283-313, 2002.
40. THANNICKAL, T.C., MOORE, R.Y., NIENHUIS, R., RAMANATHAN, L., GULYANI, S., ALDRICH, M., CORNFORD, M., AND SIEGEL, J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27: 469-474, 2000.
41. US XYREM MULTICENTER STUDY GROUP. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep, 25: 42-49, 2002.
42. VOGEL, G. Studies in psychophysiology of dreams. III. The dream of narcolepsy. Arch. Gen. Psychiatry, 3: 421-428, 1960.
43. WESTPHAL, C. Eigenthümliche mit einschlafen verbundene anfälle. Arch. J. Psychiat. 7: 631-635, 1877.
44. WILLIE, J.T., CHEMELLI, R.M., SINTON, C.M., TOKITA, S., WILLIAMS, S.C., KISANUKI, Y.Y., MARCUS, J.N., LEE, C., ELMQUIST, J.K., KOHLMEIER, K.A., LEONARD, C.S., RICHARDSON, J.A., HAMMER, R.E., AND YANAGISAWA, M. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-rem and rem sleep regulatory processes. Neuron, 38: 715-730, 2003.
45. YOSS, R.E. AND DALY, D.D. Criteria for the diagnosis of the narcoleptic syndrome. Proc. Staff Meet. Mayo Clin., 32: 320-328, 1957.
46. ZEITZER, J.M., BUCKMASTER, C.L., PARKER, K.J., HAUCK, C.M., LYONS, D.M. AND MIGNOT, E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J. Neurosci., 23: 3555-3560, 2003.